newsfilter
← Earnings
Earnings Releases·

Ardelyx — Third Quarter 2026 Earnings Summary

Ardelyx reported third-quarter 2026 total product revenue of $125.5 million, representing a 19% year-over-year increase driven by sales of IBSRELA and XPHOZAH. IBSRELA revenue grew 23% to $96.3 million, while XPHOZAH revenue increased 7% to $29.2 million. The company maintains a strong financial position with $285.3 million in cash, cash equivalents, and investments as of September 30, 2026. Additionally, Ardelyx completed enrollment ahead of schedule in its Phase 3 ACCEL clinical trial for chronic idiopathic constipation and expects to announce topline data in the second half of 2027.

Company
ARDELYX INC
Sector
Healthcare
Industry
Biotechnology